Biotech entity
pharma is the sole category represented across all 1 tracked stories. European Medicines Agency (EMA) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 7 runs above the beat's 6 for that window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. European Medicines Agency (EMA) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 7 runs above the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. Aedes albopictus appears in 1 tracked Biotech story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Aedes albopictus. Shared-story counts are live from our verified record — not editorial picks.
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
Aedes albopictus is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
